Developer docs
API playgroundTry for free, no card

Search company profiles

PainTEQ

Full company profile

uuid00006ub

Namestring
PainTEQ
Legal namestring
PainTEQ
Websiteurl
painteq.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

PainTEQ is a privately held medical device company headquartered in Tampa, Florida, that develops and commercializes minimally invasive solutions for sacroiliac (SI) joint dysfunction. Founded in 2014, the company targets interventional pain management specialists, spine surgeons, and orthopedic surgeons performing procedures in physician offices, outpatient surgical centers, and hospitals. PainTEQ's flagship product, the LinQ SI Joint Stabilization System, uses a single bone allograft implant placed via a posterior approach through a small incision and employs a patented drill-less fusion technique. The portfolio was expanded in May 2026 with TRAQ, a next-generation posterior implant engineered for bi-cortical fixation through the same tissue-sparing approach, alongside single-use surgical instruments and the OfficeLinQ in-office procedure variant.

The company operates a sales-led, direct distribution model targeting U.S.-based healthcare providers. Revenue is generated from hardware sales of implants and single-use disposable instrument kits used per procedure, with procedure-based pricing determined through physician consultation and insurance authorization; Medicare Local Coverage Determination requires two diagnostic injections with ≥75% pain relief prior to coverage. PainTEQ supports adoption through physician training and certification programs, a peer-reviewed clinical evidence base (14 published studies including a 258-patient retrospective study and the prospective SECURE and TRAQTION studies), and a sales motion anchored in clinical evidence and physician education. As of October 2025, the LinQ system had been used in over 14,000 procedures.

PainTEQ completed a $35 million financing in July 2023 led by MVolution Partners, followed by a majority growth recapitalization in August 2025 co-led by Signet Healthcare Partners and Windham Capital Partners to accelerate clinical research, product development, and U.S. expansion. The company is led by CEO Sean LaNeve and CCO Shanth Thiyagalingam, with recent additions including board member Robert Kline (October 2025) and SVP of Clinical Research Lalit Venkatesan, PhD (January 2026). PainTEQ holds 16 granted U.S. patents covering implant design, surgical instruments, and fusion methods, with operations based at its Tampa headquarters and a Riverview, Florida distribution facility.

Short descriptiontext

PainTEQ is a Tampa-based medical device company that develops and commercializes minimally invasive sacroiliac (SI) joint fusion systems, including the LinQ allograft implant and TRAQ bi-cortical fixation implant, sold to interventional pain specialists and spine surgeons across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTampa, United States
HQ citystring
Tampa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sacroiliac joint fusion, SI joint stabilization, minimally invasive spine, medical implant devices, interventional pain management
Industry1 code
1Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
CodeHLAHAEAAPrimaryYes
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Sacroiliac Joint Fusion Medical Devices
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales - Implants
TypeHardware Sales
Description

PainTEQ generates revenue from the sale of its LinQ SI Joint Stabilization System implants to healthcare providers and surgical centers. The system includes the allograft implant, single-use surgical instruments, and supporting documentation.

painteq.com
2Single-use Surgical Instruments
TypeHardware Sales
Description

Disposable surgical kit components including mating inserters, cannulas, and decorticators used during the LinQ procedure

painteq.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Procedure-based pricing through healthcare providers
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing determined through healthcare provider consultation and insurance authorization. Medicare/Local Coverage Determination requires two injections with 75% or more relief before procedure coverage.

painteq.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1LinQ
Description

The LinQ SI Joint Stabilization System - a minimally invasive posterior SI joint fusion procedure using a single allograft implant.

painteq.com
+1 more record
Core offering1 text field

PainTEQ develops, manufactures, and commercializes minimally invasive sacroiliac (SI) joint fusion medical implant systems, headlined by the LINQ SI Joint Stabilization System — a single bone allograft implant placed via a posterior, drill-less approach through a small incision in an outpatient setting. Its portfolio also includes the TRAQ bi-cortical fixation implant (U.S. commercial launch May 2026), complementary single-use surgical instrument kits, and the OfficeLinQ in-office procedure variant. These products are sold to pain management specialists, interventional spine physicians, and outpatient surgical centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 67.6% average pain relief across pain salvage study patients
+8 more records
Product overview1 text field

PainTEQ offers a portfolio of minimally invasive sacroiliac (SI) joint dysfunction solutions centered on two core implant systems: the LINQ SI Joint Stabilization System and the newer TRAQ implant. LINQ uses a single allograft implant placed via a posterior approach to stabilize the SI joint, while TRAQ provides bi-cortical fixation through the same surgical approach. Both products are complemented by single-use surgical instruments and the OfficeLinQ variant for in-office procedures. The company is expanding its evidence-based portfolio through landmark Randomized Controlled Trials, prospective studies (SECURE, TRAQTION), and biomechanics research.

Product and service4 records
1LINQ SI Joint Stabilization System
CategorySacroiliac joint fusion implant system
Description

Minimally invasive posterior sacroiliac joint fusion system that uses a single allograft implant (about the size of an almond) placed through a small incision to stabilize the dysfunctional SI joint and create an environment for long-term fusion; involves no metal implant and is performed as an outpatient/office-based procedure with faster recovery than traditional fusion. Sold to pain management specialists and interventional spine physicians.

2TRAQ
CategorySacroiliac joint fusion implant system
Description

Next-generation posterior sacroiliac joint implant designed to achieve bi-cortical fixation by engaging both the sacral and iliac cortices through a tissue-sparing 1-inch incision; the first posterior approach SI joint implant for bi-cortical fixation, expanding fixation options within PainTEQ's posterior surgical approach. Sold to interventional spine physicians and surgical centers.

3OfficeLinQ
CategorySacroiliac joint fusion procedure service model
Description

In-office version of the LINQ SI Joint Stabilization procedure that allows qualified physicians to perform the minimally invasive SI joint fusion in an office setting rather than a hospital or surgical center. Targeted at pain management practices seeking office-based procedure economics.

4Single-use Surgical Instruments
CategoryDisposable surgical instruments
Description

Single-use surgical instrument kit for the LINQ procedure, including mating inserters, cannulas, and decorticators, sold to clinicians performing SI joint fusion as a complement to the LINQ allograft implant.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-04
Description

PainTEQ collaborated with USF College of Engineering and Morsani College of Medicine on corporate-sponsored capstone projects for biomedical engineering seniors. The program serves as a workforce pipeline for the Tampa-St. Petersburg medical technology hub.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

RTI Surgical supplies surgical allografts and biologics used across spine and orthopedic procedures, including allograft implants for SI joint fusion. It is a partial-overlap, enabling peer that competes with PainTEQ's allograft-based LinQ implant on the implant-material axis.

TypeDirect peer
Description

SI-Bone is the market-leading pure-play in sacroiliac joint fusion with its iFuse Implant System, the most established lateral triangular-rod SI joint fusion device. It directly competes with PainTEQ's LinQ and TRAQ systems for the same pain management and spine surgeon customer base.

TypeEmerging player
Description

Providence Medical Technology is a privately held spine medtech company focused on cervical and adjacent-segment pathology with emerging procedural offerings. It is an adjacent emerging player in minimally invasive spine that overlaps PainTEQ in serving interventional pain and spine practices.

TypeBroad incumbent
Description

Stryker operates a large spine and orthopedic surgery portfolio and has invested in SI joint fusion offerings via its spine division. It overlaps with PainTEQ in serving interventional pain specialists and spine surgeons, with much broader scale and resources.

TypeBroad incumbent
Description

Orthofix has spine and orthopedic implant franchises (including legacy SI joint offerings) and competes with PainTEQ for interventional pain management and spine surgeon relationships, though SI joint fusion is one component of a broader portfolio.

TypeBroad incumbent
Description

Medtronic is a diversified medtech incumbent with deep spine surgery franchises and established hospital sales coverage that overlaps with PainTEQ's interventional pain and spine surgeon customers, though SI joint fusion is one of many spine subsegments it serves.

TypeBroad incumbent
Description

Globus Medical (following its merger with NuVasive) is a major spine medtech incumbent with an SI joint fusion portfolio (e.g., SIROS system) and broad hospital contracting leverage. It competes with PainTEQ across spine surgery channels while serving the same downstream SI joint patient population.

TypeDirect peer
Description

Camber Spine is a privately held spine-focused medical device company with minimally invasive SI joint fusion products (e.g., SICONUS). It is a closer-scale, niche competitor to PainTEQ targeting overlapping interventional pain and spine surgeon customers.

TypeDirect peer
Description

CoreLink Surgical (now part of Spinal Elements following acquisition) developed the Sentry SI joint fusion system, a direct lateral-approach competitor to PainTEQ's posterior LinQ and TRAQ systems in the same SI joint fusion market.

TypeBroad incumbent
Description

Alphatec is a publicly traded spine-focused medtech company with a portfolio spanning cervical, thoracolumbar, and SI joint fusion. It overlaps with PainTEQ in serving interventional spine surgeons, though at meaningfully larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PainTEQ

Sacroiliac Joint Fusion Medical Devicespainteq.com

PainTEQ is a Tampa-based medical device company that develops and commercializes minimally invasive sacroiliac (SI) joint fusion systems, including the LinQ allograft implant and TRAQ bi-cortical fixation implant, sold to interventional pain specialists and spine surgeons across the United States.

What PainTEQ does

PainTEQ is a privately held medical device company headquartered in Tampa, Florida, that develops and commercializes minimally invasive solutions for sacroiliac (SI) joint dysfunction. Founded in 2014, the company targets interventional pain management specialists, spine surgeons, and orthopedic surgeons performing procedures in physician offices, outpatient surgical centers, and hospitals. PainTEQ's flagship product, the LinQ SI Joint Stabilization System, uses a single bone allograft implant placed via a posterior approach through a small incision and employs a patented drill-less fusion technique. The portfolio was expanded in May 2026 with TRAQ, a next-generation posterior implant engineered for bi-cortical fixation through the same tissue-sparing approach, alongside single-use surgical instruments and the OfficeLinQ in-office procedure variant.

The company operates a sales-led, direct distribution model targeting U.S.-based healthcare providers. Revenue is generated from hardware sales of implants and single-use disposable instrument kits used per procedure, with procedure-based pricing determined through physician consultation and insurance authorization; Medicare Local Coverage Determination requires two diagnostic injections with ≥75% pain relief prior to coverage. PainTEQ supports adoption through physician training and certification programs, a peer-reviewed clinical evidence base (14 published studies including a 258-patient retrospective study and the prospective SECURE and TRAQTION studies), and a sales motion anchored in clinical evidence and physician education. As of October 2025, the LinQ system had been used in over 14,000 procedures.

PainTEQ completed a $35 million financing in July 2023 led by MVolution Partners, followed by a majority growth recapitalization in August 2025 co-led by Signet Healthcare Partners and Windham Capital Partners to accelerate clinical research, product development, and U.S. expansion. The company is led by CEO Sean LaNeve and CCO Shanth Thiyagalingam, with recent additions including board member Robert Kline (October 2025) and SVP of Clinical Research Lalit Venkatesan, PhD (January 2026). PainTEQ holds 16 granted U.S. patents covering implant design, surgical instruments, and fusion methods, with operations based at its Tampa headquarters and a Riverview, Florida distribution facility.

PainTEQ firmographics

Firmographics
Name
PainTEQ
Legal name
PainTEQ
Website
https://painteq.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
PainTEQ is a Tampa-based medical device company that develops and commercializes minimally invasive sacroiliac (SI) joint fusion systems, including the LinQ allograft implant and TRAQ bi-cortical fixation implant, sold to interventional pain specialists and spine surgeons across the United States.
Ownership category
akta.pro rank

PainTEQ industry classification

Industry
Product category
Sacroiliac Joint Fusion Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

Keywords

  • Sacroiliac joint fusion
  • SI joint stabilization
  • Minimally invasive spine
  • Medical implant devices
  • Interventional pain management

Where PainTEQ is headquartered

Location

Headquarters

HQ city
Tampa
HQ country
United States
HQ region
North America

Offices2 records

Markets served

PainTEQ business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Sales - Implants: PainTEQ generates revenue from the sale of its LinQ SI Joint Stabilization System implants to healthcare providers and surgical centers. The system includes the allograft implant, single-use surgical instruments, and supporting documentation.
  2. Single-use Surgical Instruments: Disposable surgical kit components including mating inserters, cannulas, and decorticators used during the LinQ procedure

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProcedure-based pricing through healthcare providers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

PainTEQ product offering

Product offering

Core offering

PainTEQ develops, manufactures, and commercializes minimally invasive sacroiliac (SI) joint fusion medical implant systems, headlined by the LINQ SI Joint Stabilization System — a single bone allograft implant placed via a posterior, drill-less approach through a small incision in an outpatient setting. Its portfolio also includes the TRAQ bi-cortical fixation implant (U.S. commercial launch May 2026), complementary single-use surgical instrument kits, and the OfficeLinQ in-office procedure variant. These products are sold to pain management specialists, interventional spine physicians, and outpatient surgical centers.

Product overview

PainTEQ offers a portfolio of minimally invasive sacroiliac (SI) joint dysfunction solutions centered on two core implant systems: the LINQ SI Joint Stabilization System and the newer TRAQ implant. LINQ uses a single allograft implant placed via a posterior approach to stabilize the SI joint, while TRAQ provides bi-cortical fixation through the same surgical approach. Both products are complemented by single-use surgical instruments and the OfficeLinQ variant for in-office procedures. The company is expanding its evidence-based portfolio through landmark Randomized Controlled Trials, prospective studies (SECURE, TRAQTION), and biomechanics research.

Differentiator

Problem solved

Functional benefit

Brands

  • LinQ: The LinQ SI Joint Stabilization System - a minimally invasive posterior SI joint fusion procedure using a single allograft implant.
  • TRAQ

Products and services

  • LINQ SI Joint Stabilization System Minimally invasive posterior sacroiliac joint fusion system that uses a single allograft implant (about the size of an almond) placed through a small incision to stabilize the dysfunctional SI joint and create an environment for long-term fusion; involves no metal implant and is performed as an outpatient/office-based procedure with faster recovery than traditional fusion. Sold to pain management specialists and interventional spine physicians.
  • TRAQ Next-generation posterior sacroiliac joint implant designed to achieve bi-cortical fixation by engaging both the sacral and iliac cortices through a tissue-sparing 1-inch incision; the first posterior approach SI joint implant for bi-cortical fixation, expanding fixation options within PainTEQ's posterior surgical approach. Sold to interventional spine physicians and surgical centers.
  • OfficeLinQ In-office version of the LINQ SI Joint Stabilization procedure that allows qualified physicians to perform the minimally invasive SI joint fusion in an office setting rather than a hospital or surgical center. Targeted at pain management practices seeking office-based procedure economics.
  • Single-use Surgical Instruments Single-use surgical instrument kit for the LINQ procedure, including mating inserters, cannulas, and decorticators, sold to clinicians performing SI joint fusion as a complement to the LINQ allograft implant.

Quantifiable outcome

  • 67.6% average pain relief across pain salvage study patients
  • +8 more outcomes

Companies that use PainTEQ

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

PainTEQ technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PainTEQ partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of South Florida (USF)minorStrategic or Co-development Partner · 4 May 2026PainTEQ collaborated with USF College of Engineering and Morsani College of Medicine on corporate-sponsored capstone projects for biomedical engineering seniors. The program serves as a workforce pipeline for the Tampa-St. Petersburg medical technology hub.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

PainTEQ competitors and assessment

Company assessment

Emerging players

  • RTI Surgical: RTI Surgical supplies surgical allografts and biologics used across spine and orthopedic procedures, including allograft implants for SI joint fusion. It is a partial-overlap, enabling peer that competes with PainTEQ's allograft-based LinQ implant on the implant-material axis.
  • Providence Medical Technology: Providence Medical Technology is a privately held spine medtech company focused on cervical and adjacent-segment pathology with emerging procedural offerings. It is an adjacent emerging player in minimally invasive spine that overlaps PainTEQ in serving interventional pain and spine practices.

Direct peers

  • SI-Bone: SI-Bone is the market-leading pure-play in sacroiliac joint fusion with its iFuse Implant System, the most established lateral triangular-rod SI joint fusion device. It directly competes with PainTEQ's LinQ and TRAQ systems for the same pain management and spine surgeon customer base.
  • Camber Spine: Camber Spine is a privately held spine-focused medical device company with minimally invasive SI joint fusion products (e.g., SICONUS). It is a closer-scale, niche competitor to PainTEQ targeting overlapping interventional pain and spine surgeon customers.
  • CoreLink Surgical: CoreLink Surgical (now part of Spinal Elements following acquisition) developed the Sentry SI joint fusion system, a direct lateral-approach competitor to PainTEQ's posterior LinQ and TRAQ systems in the same SI joint fusion market.

Broad incumbents

  • Stryker: Stryker operates a large spine and orthopedic surgery portfolio and has invested in SI joint fusion offerings via its spine division. It overlaps with PainTEQ in serving interventional pain specialists and spine surgeons, with much broader scale and resources.
  • Orthofix Medical: Orthofix has spine and orthopedic implant franchises (including legacy SI joint offerings) and competes with PainTEQ for interventional pain management and spine surgeon relationships, though SI joint fusion is one component of a broader portfolio.
  • Medtronic: Medtronic is a diversified medtech incumbent with deep spine surgery franchises and established hospital sales coverage that overlaps with PainTEQ's interventional pain and spine surgeon customers, though SI joint fusion is one of many spine subsegments it serves.
  • Globus Medical: Globus Medical (following its merger with NuVasive) is a major spine medtech incumbent with an SI joint fusion portfolio (e.g., SIROS system) and broad hospital contracting leverage. It competes with PainTEQ across spine surgery channels while serving the same downstream SI joint patient population.
  • Alphatec Holdings: Alphatec is a publicly traded spine-focused medtech company with a portfolio spanning cervical, thoracolumbar, and SI joint fusion. It overlaps with PainTEQ in serving interventional spine surgeons, though at meaningfully larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PainTEQ social profiles

Digital presence

PainTEQ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PainTEQ leadership team

Management profile

Number of profiles

Profiles4 records

PainTEQ funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PainTEQ M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PainTEQ

What does PainTEQ do?

PainTEQ develops, manufactures, and commercializes minimally invasive sacroiliac (SI) joint fusion medical implant systems, headlined by the LINQ SI Joint Stabilization System — a single bone allograft implant placed via a posterior, drill-less approach through a small incision in an outpatient setting. Its portfolio also includes the TRAQ bi-cortical fixation implant (U.S. commercial launch May 2026), complementary single-use surgical instrument kits, and the OfficeLinQ in-office procedure variant. These products are sold to pain management specialists, interventional spine physicians, and outpatient surgical centers.

Is PainTEQ a public or private company?

PainTEQ is a private company. It is classified as private equity controlled and is currently operating.

When was PainTEQ founded?

PainTEQ was founded in 2014. It employs 101 to 250 people.

Where is PainTEQ based?

PainTEQ is headquartered in Tampa, United States, in the North America region.

How does PainTEQ make money?

Two revenue lines are on record. Medical Device Sales - Implants are the primary driver. The others are single-use Surgical Instruments.

Who are PainTEQ's main competitors?

Emerging players on record are RTI Surgical and Providence Medical Technology. Direct peers are SI-Bone, Camber Spine and CoreLink Surgical. Broad incumbents are Stryker, Orthofix Medical, Medtronic, Globus Medical and Alphatec Holdings.

Does PainTEQ have an API?

No public API is recorded for PainTEQ.

What industry is PainTEQ in?

PainTEQ's product category is Sacroiliac Joint Fusion Medical Devices. Its primary akta.pro industry code is HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePainTEQ Earns Eight 2026 Top Workplaces Culture Excellence Awards and Healthcare Industry RecognitionPainTEQ, a Tampa-based chronic pain company, won eight Culture Excellence awards and a Healthcare Industry award from Energage's 2026 Top Workplaces survey. Employees rated the company 94 out of 100, with 87.3% participation. The company is expanding its posterior SI joint technology portfolio and hiring.PR NewswirePainTEQ Presents New Scientific Evidence Supporting Cortical-Piercing Posterior Sacroiliac Joint Procedures at ASPN 2026PainTEQ announced new scientific findings at the American Society of Pain and Neuroscience 2026 Annual Conference supporting its posterior sacroiliac joint fixation strategies, including the PRADA Study demonstrating that the TRAQ™ procedure's 2.5 mm cortical-piercing fixation ridges exceeded maximum cortical thickness across all demographic subgroups. A complementary finite element analysis showed improved fixation characteristics for both LINQ® and TRAQ™ procedures compared with other posterior implant designs, while preliminary real-world experience across 154 patients at 61 clinical sites reported no device- or procedure-related adverse events and encouraging early pain improvements.PR NewswirePainTEQ Announces First Patient Enrolled in the TRAQTION StudyPainTEQ announced the enrollment of the first patient in the TRAQTION Study, a prospective multicenter clinical study evaluating outcomes of posterior sacroiliac joint procedures using the TRAQ™ allograft. The study will enroll up to 100 patients across up to 10 sites in the United States over a 24-month follow-up period, assessing patient-reported outcomes, safety, and healthcare utilization. This milestone marks the beginning of a broader clinical research initiative supporting PainTEQ's commitment to evidence generation and advancing treatment options for chronic pain patients.Medical Device NetworkPainTEQ announces US launch of SI joint implantPainTEQ announced the US commercial launch of TRAQ, an implant for posterior sacroiliac joint fusion, with bi-cortical fixation via triangular barbs. The TRAQTION study will assess safety and efficacy, enrolling up to 100 subjects at ten US locations over 24 months.PR NewswirePainTEQ Launches TRAQ™, A Next-Generation Posterior Approach to SI Joint FusionPainTEQ announced the U.S. commercial launch of TRAQ™, the first posterior sacroiliac joint implant designed to achieve bi-cortical fixation by engaging both the sacral and iliac cortices through a tissue-sparing 1-inch incision. The new implant expands PainTEQ's posterior SI joint fusion platform alongside its existing LINQ® system, giving surgeons two fixation options within a single surgical approach. The company has also initiated the TRAQTION post-market study to evaluate real-world safety and efficacy of TRAQ™ across 10 U.S. sites with up to 100 subjects.WUSFCorporate sponsored capstone projects bring industry experience to USF biomedical engineering seniorsUSF biomedical engineering seniors presented 14 corporate-sponsored capstone prototypes to faculty and industry partners, completing year-long design projects with real medical device companies. Students collaborated with PainTEQ, Motiva, and Novanta on projects including a bone marrow healing device, fat-purification system, and surgical tool-tracking software. The program, a joint venture between USF's College of Engineering and Morsani College of Medicine, is positioned as a workforce pipeline for the Tampa-St. Petersburg region's growing medical technology hub.PR NewswirePainTEQ Wins Top VC/PE Honors in Tampa BayPainTEQ, a medical device company specializing in minimally invasive sacroiliac joint stabilization, won the "VC/PE Deal of the Year" award at the Tampa Bay Dealmaker Summit on February 26th. The recognition specifically honors PainTEQ's majority growth recapitalization co-led by Windham Capital Partners and Signet Healthcare Partners, along with the rapid adoption of its LinQ SI Joint Stabilization System. The award underscores the company's business trajectory, strategic clarity, and clinical impact within the healthcare ecosystem.PR NewswirePainTEQ Fuels Next Phase of Growth at NANS 2026 with Strategic Expansion of Innovation, Clinical Initiatives, and Product PortfolioPainTEQ announced significant investment in its clinical and commercial operations ahead of the NANS 2026 Annual Meeting, positioning the company for market leadership in minimally invasive sacroiliac joint dysfunction solutions. The company, which completed a 2025 recapitalization led by Signet Healthcare Partners and Windham Capital Partners, appointed Lalit Venkatesan as SVP of Clinical Research and outlined plans to launch multiple new products beginning in Q1 2026, alongside a landmark Randomized Controlled Trial and prospective studies to expand its evidence-based portfolio.PR NewswirePainTEQ Announces Appointment of Lalit Venkatesan, PhD as Senior Vice President of Clinical ResearchPainTEQ announced the appointment of Lalit Venkatesan, PhD as Senior Vice President of Clinical Research, effective immediately. Dr. Venkatesan brings more than a decade of experience in neuromodulation and medical device innovation, having previously served as Senior Director of Global Medical Affairs at Saluda Medical and held leadership roles at Abbott Neuromodulation and Natus Medical. The appointment is intended to strengthen PainTEQ's clinical research strategy and evidence generation capabilities for its portfolio of minimally invasive sacroiliac joint technologies.PR NewswirePainTEQ Scales Leadership: Med-Tech Catalyst Robert Kline Joins Board to Drive New Standard in Interventional Spine CareRobert Kline, a med-tech veteran with 25 years of experience commercializing medical devices, has joined the Board of Directors at PainTEQ. Kline, who previously founded or co-founded companies acquired by Becton Dickinson, Sartorius AG, and Hologic for up to $160 million, will help drive PainTEQ's expansion of its LinQ SI Joint Stabilization System, which has been used in over 14,000 procedures. The appointment follows a growth recapitalization and is intended to accelerate adoption of PainTEQ's minimally invasive interventional spine care technology.